ECM-Targeted Radiopharmaceutical

About Matrisome Bio

Matrisome Bio is developing a first-in-class therapeutic platform that targets the extracellular matrix (ECM), a universal and stable feature of solid tumors and metastases, to deliver radiopharmaceuticals, ADCs, and other payloads with high precision. The company's core technology involves a proprietary toolbox of ECM-specific nanobody binders designed to create a persistent drug depot at the disease site, potentially offering a superior therapeutic index across a broad range of solid tumors. Led by a team with deep expertise in oncology, ECM biology, and drug development, the seed-stage startup is advancing its lead ECM-targeted radiopharmaceutical program while building a pipeline for other indications. Matrisome Bio's approach addresses a major unmet need in metastatic cancers, where traditional therapies often fail due to tumor evolution and heterogeneity.

Therapeutic Areas

Other Metastatic Solid Tumors Drugs